Thank you very much, Madam Chair.
Thank you as well to all of our witnesses today.
I think my colleague Ms. Davies framed it very well when she said we received this very broad picture across the spectrum of the issues surrounding neurological diseases and their different stages.
I want to comment, Mr. Simmonds, on the sharing of your personal story. That always is a profound way for us to get a better understanding of what individuals are living with. When we're doing this study and we're talking about research, often we don't make that connection. So I really do appreciate your coming in.
You made a statement in your remarks that these diseases are robbing our country of intellectual capital. I think that if we can get that understanding, it will compel us to continue in our efforts towards some prevention and potentially a cure for something like Parkinson's or many other neurological diseases.
I just want to focus on another statement you made. You said timeliness and diagnosis are the issue and that diagnosis often comes too late, so then we find ourselves in that pressure of focusing on prevention but also having to ensure that individuals living with Parkinson's have the quality of life they deserve.
Actually, some of my questions are for Mr. Hu around the therapy he described for us today. You may have mentioned this in your opening remarks, but I just want to go back and ask, what provoked you to do this study in the first place?